gabapentin has been researched along with Uterine Diseases in 2 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Uterine Diseases: Pathological processes involving any part of the UTERUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the literature examining the use of gabapentin for treatment of hot flashes during natural or surgically induced menopause." | 8.87 | Use of gabapentin for the management of natural or surgical menopausal hot flashes. ( Carroll, DG; Hayes, LP; Kelley, KW, 2011) |
| "To review the literature examining the use of gabapentin for treatment of hot flashes during natural or surgically induced menopause." | 4.87 | Use of gabapentin for the management of natural or surgical menopausal hot flashes. ( Carroll, DG; Hayes, LP; Kelley, KW, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huynh, TQ | 1 |
| Patel, NR | 1 |
| Goldstein, ND | 1 |
| Makai, GE | 1 |
| Hayes, LP | 1 |
| Carroll, DG | 1 |
| Kelley, KW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures[NCT05658887] | Phase 4 | 110 participants (Anticipated) | Interventional | 2023-01-01 | Enrolling by invitation | ||
| Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management[NCT02703259] | Phase 4 | 137 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessment of the amount of narcotic use postoperatively at 2 weeks. will use opioid equivalence table to convert all narcotic use to oxycodone equivalents (NCT02703259)
Timeframe: 2 weeks
| Intervention | morphine milligram equivalents (Mean) |
|---|---|
| Gabapentin | 167.2 |
| Control | 187.3 |
Assessment of the amount of narcotic use postoperatively at 24 hours. will use opioid equivalence table to convert all narcotic use to oxycodone equivalents (NCT02703259)
Timeframe: 24 hours
| Intervention | morphine milligram equivalents (Mean) |
|---|---|
| Gabapentin | 158.8 |
| Control | 175.0 |
"Assessment of the subject pain score postoperatively at 2 weeks. will use a numeric analog scale from 0-10.~The pain scale ranging from 0-10 with 0 representing No Pain and 10 representing the Worst Pain Possible" (NCT02703259)
Timeframe: 2 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 1.3 |
| Control | 1.4 |
Pain score assesses patient subjective pain via patient reported numeric analogue scale, range 0-10 with 0 being no pain and 10 being severe pain. (NCT02703259)
Timeframe: 24 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 3.4 |
| Control | 3.4 |
Will assess for known symptoms of gabapentin postoperatively at 2 weeks. We will survey subjects regarding their experience of the following symptoms: dizziness/drowsiness, fatigue, loss of balance, blurry vision, tremulousness, swelling, nausea, vomiting, diarrhea, and allergic reaction (NCT02703259)
Timeframe: 2 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Dizziness | Blurred vision | Somnolence | Difficulty walking | Tremulousness | Nausea | Vomiting | |
| Control | 8 | 3 | 21 | 5 | 2 | 7 | 1 |
| Gabapentin | 12 | 4 | 18 | 5 | 4 | 12 | 0 |
Will assess for known symptoms of gabapentin postoperatively at 24 hours. We will survey subjects regarding their experience of the following symptoms: dizziness/drowsiness, fatigue, loss of balance, blurry vision, tremulousness, swelling, nausea, vomiting, diarrhea, and allergic reaction (NCT02703259)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Dizziness | Blurred Vision | Somnolence | Difficulty walking | Tremulousness | Nausea | Vomiting | |
| Control | 8 | 4 | 23 | 11 | 6 | 25 | 15 |
| Gabapentin | 17 | 7 | 20 | 13 | 11 | 24 | 9 |
1 review available for gabapentin and Uterine Diseases
| Article | Year |
|---|---|
Use of gabapentin for the management of natural or surgical menopausal hot flashes.
Topics: Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyri | 2011 |
1 trial available for gabapentin and Uterine Diseases
| Article | Year |
|---|---|
Preoperative Gabapentin for Minimally Invasive Hysterectomy: A Randomized Controlled Trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Celecoxib; Double-Blind Method; Drug Administration | 2021 |
Preoperative Gabapentin for Minimally Invasive Hysterectomy: A Randomized Controlled Trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Celecoxib; Double-Blind Method; Drug Administration | 2021 |
Preoperative Gabapentin for Minimally Invasive Hysterectomy: A Randomized Controlled Trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Celecoxib; Double-Blind Method; Drug Administration | 2021 |
Preoperative Gabapentin for Minimally Invasive Hysterectomy: A Randomized Controlled Trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Celecoxib; Double-Blind Method; Drug Administration | 2021 |